Small vessel vasculitis of the lung

Interstitial Lung Disease Program, National Jewish Medical and Research Center, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA The diagnosis and management of SVV remains one of the most challenging clinical scenarios encountered by a clinician. Careful attention to detail and a thorough knowledge of the specific disorders, their therapies, and complications thereof is required to optimally care for these patients. The recent completion of a number of randomized, controlled, multicenter clinical trials has greatly improved our knowledge base and ability to care for vasculitis patient. The next decade holds even more promise.

[1]  C. Kallenberg,et al.  Association of autoantibodies to myeloperoxidase with different forms of vasculitis. , 2010, Arthritis and rheumatism.

[2]  F. Woude Taking anti‐neutrophil cytoplasmic antibody (ANCA) testing beyond the limits , 2002 .

[3]  M. Heller,et al.  Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. , 2002, Rheumatology.

[4]  L. Guillevin,et al.  Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. , 2002, Rheumatology.

[5]  K. Brown,et al.  Vasculitis: Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, polyarteritis nodosa, and Takayasu arteritis. , 2002, Critical care clinics.

[6]  J. Katz,et al.  Using antineutrophil cytoplasmic antibody testing to diagnose vasculitis: can test-ordering guidelines improve diagnostic accuracy? , 2002, Archives of internal medicine.

[7]  K. De Groot,et al.  High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. , 2002, Arthritis and rheumatism.

[8]  M. Haubitz,et al.  Tolerance of mycophenolate mofetil in end-stage renal disease patients with ANCA-associated vasculitis. , 2002, Clinical nephrology.

[9]  D. Schroeder,et al.  Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. , 2002, Clinical immunology.

[10]  W. Koldingsnes,et al.  Predictors of survival and organ damage in Wegener's granulomatosis. , 2002, Rheumatology.

[11]  G. Hoffman,et al.  Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s. , 2002, The Journal of rheumatology.

[12]  M. Hogan,et al.  Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. , 2001, Arthritis and rheumatism.

[13]  D. Adu,et al.  The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  M. Kimura,et al.  Generalized Wegener's granulomatosis responding to sulfamethoxazole-trimethoprim monotherapy. , 2001, Internal medicine.

[15]  G A Colditz,et al.  Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies. , 2001, The Journal of rheumatology.

[16]  R. Solans,et al.  Churg-Strauss syndrome: outcome and long-term follow-up of 32 patients. , 2001, Rheumatology.

[17]  C. Pusey,et al.  Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. , 2001, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[18]  J. Stone,et al.  Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety. , 2001, Arthritis and rheumatism.

[19]  L. Bostad,et al.  Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  L. Guillevin,et al.  Analysis of factors predictive of survival based on 49 patients with systemic Wegener's granulomatosis and prospective follow-up. , 2001, Rheumatology.

[21]  L. Guillevin,et al.  Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. , 2001, Arthritis and rheumatism.

[22]  C. Kallenberg,et al.  Novel therapies for anti-neutrophil cytoplasmic antibody-associated vasculitis , 2001, Current opinion in nephrology and hypertension.

[23]  P. Lamprecht,et al.  Prevalence and spectrum of rheumatic diseases associated with proteinase 3-antineutrophil cytoplasmic antibodies (ANCA) and myeloperoxidase-ANCA. , 2001, Rheumatology.

[24]  M. André,et al.  Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener's granulomatosis? A prospective study. , 2001, Rheumatology.

[25]  M. Madaio,et al.  The diagnosis of glomerular diseases: acute glomerulonephritis and the nephrotic syndrome. , 2001, Archives of internal medicine.

[26]  D. Jayne Update on the European Vasculitis Study Group trials , 2001, Current opinion in rheumatology.

[27]  J Stebbing,et al.  Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. , 2000, Arthritis care and research : the official journal of the Arthritis Health Professions Association.

[28]  C. Langford,et al.  Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis. Long-term renal outcome in patients with glomerulonephritis. , 2000, Arthritis and rheumatism.

[29]  D. Adu,et al.  Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. , 2000, QJM : monthly journal of the Association of Physicians.

[30]  D. Jayne Evidence-based treatment of systemic vasculitis. , 2000, Rheumatology.

[31]  C. Kallenberg,et al.  New treatments of ANCA-associated vasculitis. , 2000, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[32]  Søren Freiesleben Sørensen,et al.  A prospective study of vasculitis patients collected in a five year period: evaluation of the Chapel Hill nomenclature , 2000, Annals of the rheumatic diseases.

[33]  M. Heller,et al.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. , 2000, Arthritis and rheumatism.

[34]  L. Vatten,et al.  Wegener's granulomatosis: clinical course in 108 patients with renal involvement. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  M. Haas,et al.  Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  D. Scott,et al.  Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. , 2000, Arthritis and rheumatism.

[37]  K. Andrassy,et al.  Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. , 1999, Journal of the American Society of Nephrology : JASN.

[38]  E. Mirapeix,et al.  Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[39]  J. Stone,et al.  Treatment of non-life threatening Wegener's granulomatosis with methotrexate and daily prednisone as the initial therapy of choice. , 1999, The Journal of rheumatology.

[40]  Y. Shoenfeld,et al.  Marked improvement of Churg-Strauss vasculitis with intravenous gammaglobulins. , 1999, Southern medical journal.

[41]  R J Falk,et al.  International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) , 1999, American journal of clinical pathology.

[42]  J. Amouroux,et al.  Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. , 1999, Arthritis and rheumatism.

[43]  T. Pincus,et al.  Limitations of the 1990 American College of Rheumatology Classification Criteria in the Diagnosis of Vasculitis , 1998, Annals of Internal Medicine.

[44]  M. Heller,et al.  Pulmonary Wegener's granulomatosis: correlation between high-resolution CT findings and clinical scoring of disease activity. , 1998, Chest.

[45]  L. Guillevin,et al.  Polyarteritis nodosa, microscopic polyangiitis and Churg–Strauss syndrome , 1998, Lupus.

[46]  K. De Groot,et al.  Induction of remission in Wegener's granulomatosis with low dose methotrexate. , 1998, The Journal of rheumatology.

[47]  P Lesavre,et al.  Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. , 1998, Kidney international.

[48]  K. Dalhoff,et al.  Efficacy of transbronchial biopsy in pulmonary vaculitides. , 1997, The European respiratory journal.

[49]  R. Gherardi,et al.  Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: clinical aspects, neurologic manifestations, and treatment. , 1997, Neurologic clinics.

[50]  M. Zamora,et al.  Diffuse Alveolar Hemorrhage and Systemic Lupus Erythematosus: Clinical Presentation, Histology, Survival, and Outcome , 1997, Medicine.

[51]  Bolton Wk RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS , 1996 .

[52]  G. Hunder,et al.  Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. , 1996, The American journal of medicine.

[53]  C. Kallenberg,et al.  Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis , 1996 .

[54]  E. Böttinger,et al.  The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. , 1996, Archives of internal medicine.

[55]  W. Gross,et al.  Antineutrophil cytoplasmic autoantibody testing in vasculitides. , 1995, Rheumatic diseases clinics of North America.

[56]  O. Lortholary,et al.  Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. , 1995, Arthritis and rheumatism.

[57]  R. Saxena,et al.  Circulating autoantibodies as serological markers in the differential diagnosis of pulmonary renal syndrome , 1995, Journal of internal medicine.

[58]  R. Falk,et al.  Clinical and pathological classification of ANCA‐associated vasculitis: what are the controversies? , 1995, Clinical and experimental immunology.

[59]  Guy Hoffman,et al.  An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. , 1995, Arthritis and rheumatism.

[60]  R. Porter Nomenclature of Systemic Vasculitides: Proposal of an International Consensus Conference , 1995 .

[61]  L. Noel,et al.  Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. , 1995, Clinical and experimental rheumatology.

[62]  A. Dash,et al.  Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[63]  U. Specks,et al.  Anti-neutrophil cytoplasmic antibodies. , 1994, Mayo Clinic proceedings.

[64]  L. Calabrese,et al.  Neurologic manifestations of systemic vasculitides. , 1994, Seminars in neurology.

[65]  R. Moots,et al.  Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. , 1994, QJM : monthly journal of the Association of Physicians.

[66]  R. Falk,et al.  The pathology of vasculitis involving the kidney. , 1994, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[67]  L. Noel,et al.  Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome--62 patients. , 1994, The Journal of rheumatology.

[68]  R J Falk,et al.  Nomenclature of systemic vasculitides. Proposal of an international consensus conference. , 1994, Arthritis and rheumatism.

[69]  D. Adu,et al.  Relapses in patients with a systemic vasculitis. , 1993, The Quarterly journal of medicine.

[70]  A. D'apice,et al.  Wegener's granulomatosis: clinical features and prognosis in 37 patients. , 1993, Australian and New Zealand journal of medicine.

[71]  L. Revert,et al.  Antimyeloperoxidase autoantibody-associated necrotizing alveolar capillaritis. , 1992, The American review of respiratory disease.

[72]  Guy Hoffman,et al.  The treatment of Wegener's granulomatosis with glucocorticoids and methotrexate. , 1992, Arthritis and rheumatism.

[73]  J. Grünfeld,et al.  Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis , 1992, Clinical and experimental immunology.

[74]  A. Douglas,et al.  Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. , 1992, The Quarterly journal of medicine.

[75]  Guy Hoffman,et al.  Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.

[76]  C. Pusey,et al.  Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. , 1991, Kidney international.

[77]  R. Goldschmeding,et al.  Antimyeloperoxidase antibodies in the Churg-Strauss syndrome , 1991, Thorax.

[78]  T. Carey,et al.  Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. , 1990, Annals of internal medicine.

[79]  Guy Hoffman,et al.  Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. , 1990, The American journal of medicine.

[80]  Guy Hoffman,et al.  Interpretation of Head and Neck Biopsies in Wegener's Granulomatosis: A Pathologic Study of 126 Biopsies in 70 Patients , 1990, The American journal of surgical pathology.

[81]  R. Loire,et al.  Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. , 1990, Chest.

[82]  A. Stuck,et al.  Risk of infectious complications in patients taking glucocorticosteroids. , 1989, Reviews of infectious diseases.

[83]  C. Kallenberg,et al.  Association between active Wegener's granulomatosis and anticytoplasmic antibodies. , 1989, Archives of internal medicine.

[84]  Bousser Mg,et al.  Vasculitis of the central nervous system , 1989 .

[85]  R. Swerlick,et al.  Cutaneous vasculitis: its relationship to systemic disease. , 1989, The Medical clinics of North America.

[86]  U. Specks,et al.  Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. , 1989, Annals of internal medicine.

[87]  A. Fauci,et al.  Response: The role of trimethoprim/sulfamethoxazole in the treatment of Wegener's granulomatosis , 1988 .

[88]  R. Falk,et al.  Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. , 1988, The New England journal of medicine.

[89]  D. Scott,et al.  Polyarteritis and the kidney. , 1987, The Quarterly journal of medicine.

[90]  J. Crissman,et al.  Segmental necrotizing glomerulonephritis: diagnostic, prognostic, and therapeutic significance. , 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[91]  C. Savage,et al.  Microscopic polyarteritis: presentation, pathology and prognosis. , 1985, The Quarterly journal of medicine.

[92]  G. Hughes,et al.  Systemic Vasculitis with Asthma and Eosinophilia: A Clinical Approach to the Churg‐Strauss Syndrome , 1984, Medicine.

[93]  A. Fauci,et al.  Neurologic manifestations of systemic vasculitis. A retrospective and prospective study of the clinicopathologic features and responses to therapy in 25 patients. , 1981, American Journal of Medicine.

[94]  Hans C van Houwelingen,et al.  Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. , 2002, Kidney international.

[95]  F. J. van der Woude Taking anti-neutrophil cytoplasmic antibody (ANCA) testing beyond the limits. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[96]  J. P. Venetz,et al.  [Microscopic polyangiitis]. , 2000, Annales de medecine interne.

[97]  L. Guillevin,et al.  Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. , 1999, Medicine.

[98]  D. Jayne Pulmonary-Renal Syndrome , 1998 .

[99]  G. Hoffman,et al.  Antineutrophil cytoplasmic antibodies. , 1998, Arthritis and rheumatism.

[100]  G. Hoffman,et al.  Pulmonary vasculitis. , 1998, Clinics in chest medicine.

[101]  M. Cotch,et al.  The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. , 1996, Arthritis and rheumatism.

[102]  R. Falk,et al.  Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. , 1996, Journal of the American Society of Nephrology : JASN.

[103]  W. K. Bolton Rapidly progressive glomerulonephritis. , 1996, Seminars in nephrology.

[104]  O. Lortholary,et al.  Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. , 1996, Medicine.

[105]  M. Heller,et al.  Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. , 1996, QJM : monthly journal of the Association of Physicians.

[106]  C. Kallenberg,et al.  Association of Chronic Nasal Carriage of Staphylococcus aureus and Higher Relapse Rates in Wegener Granulomatosis , 1994, Annals of Internal Medicine.

[107]  C. Hallahan,et al.  Limited prognostic value of changes in antineutrophil cytoplasmic antibody titers in patients with Wegener's granulomatosis. , 1993, Advances in experimental medicine and biology.

[108]  C. Pusey,et al.  Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[109]  K. Brandt,et al.  Infectious complications of cyclophosphamide treatment for vasculitis. , 1989, Arthritis and rheumatism.

[110]  B. Haynes,et al.  Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. , 1983, Annals of internal medicine.